PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsHepatitis c
MeSH D006526 - hepatitis c
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D018178:Flaviviridae infections
0 Companies
0 Drugs
Success rate
D006525:Viral hepatitis human
0 Companies
0 Drugs
Success rate
D000086982:Blood-borne infections
0 Companies
0 Drugs
Success rate
D006526: 
Hepatitis c
7 Companies
16 Drugs
$
Success rate
D019698:Chronic hepatitis c
20 Companies
22 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaSofosbuvir Sofosbuvir  2022-01-27   
Johnson & JohnsonTelaprevir Incivo  2011-09-19   
Simeprevir Olysio 2025-05-19 2013-11-22   
AbbVieDasabuvir Exviera  2015-01-14   
Glecaprevir, Pibrentasvir Maviret  2017-07-26   
Glecaprevir, Pibrentasvir Mavyret 2030-06-10 2017-08-03 $1,397 M Q3/23-Q2/24 
Ritonavir, Ombitasvir, Paritaprevir Technivie 2024-08-25 2015-07-24   
Ritonavir, Dasabuvir, Ombitasvir, Paritaprevir Viekira 2024-08-25 2014-12-19 $16 M Q2/19-Q1/20 
Ritonavir, Ombitasvir, Paritaprevir Viekirax  2015-01-14   
Merck & CoBoceprevir Victrelis 2024-12-22 2011-05-13   
Elbasvir, Grazoprevir Zepatier 2029-07-24 2016-01-28 $167 M Y2020 
Bristol Myers SquibbDaclatasvir Daklinza 2027-08-08 2015-07-24 $1,312 M Q1/15-Q1/16 
Gilead SciencesSofosbuvir, Velpatasvir Epclusa 2028-03-21 2016-06-28 $2,424 M Q3/17-Q3/18 
Sofosbuvir, Ledipasvir Harvoni 2028-03-21 2014-10-10 $1,537 M Y2023 
Sofosbuvir Sovaldi 2028-03-21 2013-12-06 $964 M Y2017 
Sofosbuvir, Velpatasvir, Voxilaprevir Vosevi 2028-03-21 2017-07-18 $188 M Q4/19-Q3/20 
Vertex PharmaceuticalsTelaprevir Incivek 2025-02-25 2011-05-23   
Clinical Trials
Historical Success Rate
Phase 1
60%
48/80
Phase 2
72%
48/67
Phase 3
71%
48/68
Approved: 15Overall Success rate: 30%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
PIDILIZUMAB
Johnson & Johnson
Telaprevir,
Simeprevir,
Enoblituzumab,
Ademetionine,
Adafosbuvir,
Aspartame,
Odalasvir,
SAMATASVIR,
Mk0518,
TMC647055,
Arm1,
Arm2,
Haart,
Evidence,
IDX719
AbbVie
Ritonavir,
Dasabuvir,
Glecaprevir,
Ombitasvir,
Paritaprevir,
Pibrentasvir,
Tozadenant,
Alfacalcidol,
Bevifimod,
Corticorelin,
Nadide,
Diamorphine,
Viaject,
Cam2038,
Mk0518,
Vekirax,
Marvelon,
Daas,
Arm1,
Arm2,
Diacetylmorphine,
Nmda,
Evidence,
Subutex
Merck & Co
Elbasvir,
Grazoprevir,
Boceprevir,
Escitalopram,
Benzocaine,
Docusate,
Benzylpenicillin,
Antithrombin iii,
Vitamin e,
Narlaprevir,
Vaniprevir,
Alanine,
Ademetionine,
Edrecolomab,
Tenofovir,
Pegargiminase,
Interferon alfacon-1,
Albinterferon alfa-2b,
Aspartame,
Bevifimod,
BIMIRALISIB,
Corticorelin,
Nadide,
Perfosfamide,
RUZASVIR,
SAMATASVIR,
Tiratricol,
UPRIFOSBUVIR,
Valine,
VALOPICITABINE,
Sodium polystyrene sulfonate,
Fendrix,
Viaject,
Cam2038,
Ccb,
Lexapro,
Mk0518,
Rgt,
TMC647055,
Gcsf,
Idx21459,
Daas,
Antacid,
Arm1,
Arm2,
IDX184,
Ssri,
Cocoa,
Evidence,
IDX719,
Kcl,
Pbo,
Subutex
Bristol Myers Squibb
Daclatasvir,
Escitalopram,
Vitamin e,
Asunaprevir,
Beclabuvir,
Tarenflurbil,
Alfacalcidol,
Pegargiminase,
Albinterferon alfa-2b,
Corticorelin,
Tiratricol,
Fendrix,
Gladem,
Ocp,
Cam2038,
Lexapro,
Tvr,
Bcv,
Mevalotin,
Arm1,
Betaloc,
Trinessa,
Arm2,
Ssri,
Pbo,
Subutex
Gilead Sciences
Sofosbuvir,
Velpatasvir,
Ledipasvir,
Voxilaprevir,
Danoprevir,
Benzocaine,
Enoblituzumab,
Asunaprevir,
Ademetionine,
Tenofovir,
Doconexent,
Pegargiminase,
Aspartame,
Bevifimod,
Corticorelin,
NIVOCASAN,
RADALBUVIR,
SIMTUZUMAB,
TEGOBUVIR,
VEDROPREVIR,
VESATOLIMOD,
Fendrix,
Cam2038,
Mk0518,
Rpv,
Marvelon,
Rgt,
VDV,
Daas,
Arm1,
Pcd,
Trinessa,
Arm2,
Subutex
Vertex Pharmaceuticals
Telaprevir,
Benzocaine,
Vitamin e,
Ademetionine,
Pegargiminase,
Albinterferon alfa-2b,
Aspartame,
LOMIBUVIR,
MERIMEPODIB,
Retinol,
Cam2038,
Mk0518,
Tvr,
Trinessa,
Haart,
Pbo,
Subutex
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use